Takeda To Acquire IDM Pharma (IDMI) at 55% Premium
More News related to IDMI
- Unusual 11 Mid-Day Movers 5/18: KONA, IDMI, GRO, REDF Higher; SPIR, EDZ, COIN, FAZ Lower
- Notable Mergers and Acquisitions of the Day 5/18: KONA, IDMI, CF/AGU, VR/IPCR, AMSWA/LGTY
- Morning Movers 5/18: KONA, AHR, IDMI, LGTY, IBN, HEB Higher; SPIR, COIN, BIDZ, AYE Lower
- Takeda To Acquire IDM Pharma (IDMI) at 55% Premium
- IDM Pharma (IDMI) Reports Q4 Loss of $0.07
More News related to Mergers and Acquisitions
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
- Unusual 11 Mid-Day Movers 11/25: RTK, QADI, QBC, KBX Higher; BNHNA, DRAM, TBH, CWTR Lower
- Afternoon ETF Check: UNG, XRT, EWJ Up; VNM, RSX Down
- Notable Analyst Ratings Changes 11/25: EXXI, IWA, VPRT Upgraded; BNHN, NRG, GTE Downgraded
- Notable Mergers and Acquisitions of the Day 11/25: PEET/DDRX/GMCR, ERIC, URX
Takeda Pharmaceutical Company Limited agreed to acquire IDM Pharma, Inc. (Nasdaq: IDMI) for US$2.64 per share in cash.
Shares of IDMI closed at $1.70 per share on Friday, representing a deal premium of 55%.
Millennium: The Takeda Oncology Company, Takeda's business unit responsible for global oncology strategy and development, will have global development responsibility for MEPACT, IDM Pharma's primary asset, and Takeda Pharmaceuticals Europe Ltd. will be responsible for commercializing MEPACT in Europe.
IDM Pharma received European marketing approval for MEPACT, a therapy indicated for the treatment of non-metastatic osteosarcoma (malignant bone cancer) following surgical removal of the tumor (resection) in children, adolescents and young adults. Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
